Wockhardt’s Fifth Novel Antibiotic, Foviscu,^® (WCK 4282), Matches Gold – Standard Meropenem in pivotal Phase 3 Trial as First – Line Therapies Fail Against Rising Resistance

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.